Anthem Biosciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Anthem Biosciences, a pharma/CRDO company that recently listed on NSE/BSE on July 21, 2025, reported its first quarterly results as a listed entity for Q1 FY26. Standalone revenue from operations jumped about 59% year-on-year to Rs 5,380.11 Mn (vs Rs 3,385.39 Mn in Q1 FY25). Standalone profit after tax rose about 74% to Rs 1,483.40 Mn (vs Rs 853.36 Mn), translating to a basic EPS of Rs 2.65 (vs Rs 1.53). On a consolidated basis, including subsidiary Neoanthem Lifesciences (which posted a Rs 125.5 Mn loss), revenue grew nearly 60% to Rs 5,402.09 Mn and PAT rose about 65% to Rs 1,357.91 Mn. Statutory auditor K.P. Rao & Co. issued an unqualified limited review report on both standalone and consolidated results. The board also approved the re-designation of Mr. Ravi Kalla as Chief Information Officer, and 2.53 lakh ESOP shares were allotted during the quarter.
A strong debut quarter with double-digit revenue and profit growth on both standalone and consolidated bases is likely to be received positively by the market, reinforcing confidence in the newly-listed stock. Investors should note the drag from the loss-making subsidiary and watch how it trends going forward.